|
1
|
Denholm R, Schüz J, Straif K, Stücker I,
Jöckel KH, Brenner DR, De Matteis S, Boffetta P, Guida F, Brüske I,
et al: Is previous respiratory disease a risk factor for lung
cancer? Am J Respir Crit Care Med. 190:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chambers SK, Dunn J, Occhipinti S, Hughes
S, Baade P, Sinclair S, Aitken J, Youl P and O'Connell DL: A
systematic review of the impact of stigma and nihilism on lung
cancer outcomes. BMC Cancer. 12:1842012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dai X, Zhang J, Guo G, Cai Y, Cui R, Yin
C, Liu W, Vinothkumar R, Zhang T, Liang G and Zhang X: A
mono-carbonyl analog of curcumin induces apoptosis in
drug-resistant EGFR-mutant lung cancer through the generation of
oxidative stress and mitochondrial dysfunction. Cancer Manag Res.
10:3069–3082. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chong CR and Janne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Shaughnessy J, Thaddeus Beck J and Royce
M: Everolimus-based combination therapies for HR+, HER2- metastatic
breast cancer. Cancer Treat Rev. 69:204–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bajetta E, Catena L, Pusceddu S, Spada F,
Iannacone C, Sarno I, Di Menna G, Dottorini L and Marte AM:
Everolimus in combination with octreotide long-acting repeatable in
a first-line setting for patients with neuroendocrine tumors: A
5-year update. Neuroendocrinology. 106:307–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao X, Jegede O, Gray C, Catalano PJ,
Novak J, Kwiatkowski DJ, McKay RR, George DJ, Choueiri TK,
McDermott DF, et al: Comprehensive genomic profiling of metastatic
tumors in a phase 2 biomarker study of everolimus in advanced renal
cell carcinoma. Clin Genitourin Cancer. 16:341–348. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dubois M, Le Joncour V, Tonon MC, Anouar
Y, Proust F, Morin F, Gandolfo P, Joly F, Hilber P and Castel H:
Evaluation of the impact of the cancer therapy everolimus on the
central nervous system in mice. PLoS One. 9:e1135332014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirashima K, Baba Y, Watanabe M, Karashima
RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI and Baba H:
Aberrant activation of the mTOR pathway and anti-tumour effect of
everolimus on oesophageal squamous cell carcinoma. Br J Cancer.
106:876–882. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wahl M, Chang SM, Phillips JJ, Molinaro
AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ,
Berger M, et al: Probing the phosphatidylinositol
3-kinase/mammalian target of rapamycin pathway in gliomas: A phase
2 study of everolimus for recurrent adult low-grade gliomas.
Cancer. 123:4631–4639. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park IH, Kong SY, Kwon Y, Kim MK, Sim SH,
Joo J and Lee KS: Phase I/II clinical trial of everolimus combined
with gemcitabine/cisplatin for metastatic triple-negative breast
cancer. J Cancer. 9:1145–1151. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng W, Han W, Fan T, Wang X, Cheng Z, Wan
B and Chen J: Scutellarin inhibits human renal cancer cell
proliferation and migration via upregulation of PTEN. Biomed
Pharmacother. 107:1505–1513. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen CY, Chen J, He L and Stiles BL: PTEN:
Tumor suppressor and metabolic regulator. Front Endocrinol
(Lausanne). 9:3382018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li ZH, Li L, Kang LP and Wang Y:
MicroRNA-92a promotes tumor growth and suppresses immune function
through activation of MAPK/ERK signaling pathway by inhibiting PTEN
in mice bearing U14 cervical cancer. Cancer Med. May 11–2018.(Epub
ahead of print).
|
|
16
|
Chu P, Liang A, Jiang A and Zong L:
miR-205 regulates the proliferation and invasion of ovarian cancer
cells via suppressing PTEN/SMAD4 expression. Oncol Lett.
15:7571–7578. 2018.PubMed/NCBI
|
|
17
|
Wu RL, Ali S, Sarkar FH and Beydoun R:
Identification of differentially expressed miRNAs in appendiceal
mucinous cystadenocarcinoma from mucinous cystadenoma. J Cancer Sci
Ther. 7:328–335. 2015.PubMed/NCBI
|
|
18
|
Chang M, Lin H, Luo M, Wang J and Han G:
Integrated miRNA and mRNA expression profiling of tension
force-induced bone formation in periodontal ligament cells. In
Vitro Cell Dev Biol Anim. 51:797–807. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res. 46:D296–D302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seront E, Pinto A, Bouzin C, Bertrand L,
Machiels JP and Feron O: PTEN deficiency is associated with reduced
sensitivity to mTOR inhibitor in human bladder cancer through the
unhampered feedback loop driving PI3K/Akt activation. Br J Cancer.
109:1586–1592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee KE, Hahm E, Bae S, Kang JS and Lee WJ:
The enhanced tumor inhibitory effects of gefitinib and L-ascorbic
acid combination therapy in non-small cell lung cancer cells. Oncol
Lett. 14:276–282. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao H, Yu S, Chen D, Jing C, Wang Z, Ma R,
Liu S, Ni J, Feng J and Wu J: Liver X receptor agonist T0901317
reverses resistance of A549 human lung cancer cells to EGFR-TKI
treatment. FEBS Open Bio. 7:35–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang L, Yang H, Lei Z, Zhao J, Chen Y,
Chen P, Li C, Zeng Y, Liu Z, Liu X and Zhang HT: Repression of
TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal
transition in non-small-cell lung cancer. Oncogene. 35:867–877.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi Y, Zhang W, Ye Y, Cheng Y, Han L, Liu
P, Zhao W, Tong Z and Yu J: Benefit of everolimus as a monotherapy
for a refractory breast cancer patient bearing multiple genetic
mutations in the PI3K/AKT/mTOR signaling pathway. Cancer Biol Med.
15:314–321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Manegold PC, Paringer C, Kulka U, Krimmel
K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M and Bruns CJ:
Antiangiogenic therapy with mammalian target of rapamycin inhibitor
RAD001 (Everolimus) increases radiosensitivity in solid cancer.
Clin Cancer Res. 14:892–900. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Powell JD, Pollizzi KN, Heikamp EB and
Horton MR: Regulation of immune responses by mTOR. Annu Rev
Immunol. 30:39–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dos Santos C, Tijeras-Raballand A, Serova
M, Sebbagh S, Slimane K, Faivre S, de Gramont A and Raymond E:
Effects of preset sequential administrations of sunitinib and
everolimus on tumour differentiation in Caki-1 renal cell
carcinoma. Br J Cancer. 112:86–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pavel M, O'Toole D, Costa F, Capdevila J,
Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, et
al: ENETS consensus guidelines update for the management of distant
metastatic disease of intestinal, pancreatic, bronchial
neuroendocrine neoplasms (NEN) and NEN of unknown primary site.
Neuroendocrinology. 103:172–185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferolla P, Brizzi MP, Meyer T, Mansoor W,
Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W,
et al: Efficacy and safety of long-acting pasireotide or everolimus
alone or in combination in patients with advanced carcinoids of the
lung and thymus (LUNA): An open-label, multicentre, randomised,
phase 2 trial. Lancet Oncol. 18:1652–1664. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lane HA, Wood JM, McSheehy PM, Allegrini
PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM,
Martiny-Baron G, Schnell CR, et al: mTOR inhibitor RAD001
(everolimus) has antiangiogenic/vascular properties distinct from a
VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 15:1612–1622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kuwahara Y, Mori M, Kitahara S and
Fukumoto M, Ezaki T, Mori S, Echigo S, Ohkubo Y and Fukumoto M:
Targeting of tumor endothelial cells combining 2 Gy/day of X-ray
with everolimus is the effective modality for overcoming clinically
relevant radioresistant tumors. Cancer Med. 3:310–321. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zeng Y, Tian X, Wang Q, He W, Fan J and
Gou X: Attenuation of everolimus-induced cytotoxicity by a
protective autophagic pathway involving ERK activation in renal
cell carcinoma cells. Drug Des Devel Ther. 12:911–920. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Johnbeck CB, Munk Jensen M, Haagen Nielsen
C, Fisker Hag AM, Knigge U and Kjaer A: 18F-FDG and 18F-FLT-PET
imaging for monitoring everolimus effect on tumor-growth in
neuroendocrine tumors: Studies in human tumor xenografts in mice.
PLoS One. 9:e913872014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Di Nicolantonio F, Arena S, Tabernero J,
Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin
D, Mazzucchelli L, et al: Deregulation of the PI3K and KRAS
signaling pathways in human cancer cells determines their response
to everolimus. J Clin Invest. 120:2858–2866. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang SI, Parsons R and Ittmann M:
Homozygous deletion of the PTEN tumor suppressor gene in a subset
of prostate adenocarcinomas. Clin Cancer Res. 4:811–815.
1998.PubMed/NCBI
|
|
38
|
Wang X, Huang H and Young KH: The PTEN
tumor suppressor gene and its role in lymphoma pathogenesis. Aging
(Albany NY). 7:1032–1049. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lotan TL, Wei W, Ludkovski O, Morais CL,
Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, et
al: Analytic validation of a clinical-grade PTEN
immunohistochemistry assay in prostate cancer by comparison with
PTEN FISH. Mod Pathol. 29:904–914. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Scully MM, Palacios-Helgeson LK, Wah LS
and Jackson TA: Rapid estrogen signaling negatively regulates PTEN
activity through phosphorylation in endometrial cancer cells. Horm
Cancer. 5:218–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsutsui S, Inoue H, Yasuda K, Suzuki K,
Higashi H, Era S and Mori M: Reduced expression of PTEN protein and
its prognostic implications in invasive ductal carcinoma of the
breast. Oncology. 68:398–404. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mereniuk TR, El Gendy MA, Mendes-Pereira
AM, Lord CJ, Ghosh S, Foley E, Ashworth A and Weinfeld M: Synthetic
lethal targeting of PTEN-deficient cancer cells using selective
disruption of polynucleotide kinase/phosphatase. Mol Cancer Ther.
12:2135–2144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Simpson L and Parsons R: PTEN: Life as a
tumor suppressor. Exp Cell Res. 264:29–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tang Y and Eng C: PTEN autoregulates its
expression by stabilization of p53 in a phosphatase-independent
manner. Cancer Res. 66:736–742. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bjaanaes MM, Halvorsen AR, Solberg S,
Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M,
Pastorino U, Kure E, et al: Unique microRNA-profiles in
EGFR-mutated lung adenocarcinomas. Int J Cancer. 135:1812–1821.
2014. View Article : Google Scholar : PubMed/NCBI
|
